Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | HEXA | P06865 | 5/20 | 0.34 |
| ▸ | HEXB | P07686 | 5/20 | 0.34 |
| ▸ | DHFR | P00374 | 4/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427027 | 1.00 | CCR4 (0.38) | CCR4KMT2AHTTMAPKAPK2EDNRA | |
| SCHEMBL11229329 | 0.80 | CCR4 (0.39) | CCR4EDNRA | |
| SCHEMBL14703937 | 0.80 | HTT (0.37) | KMT2AHTTMAPKAPK2ATR | |
| SCHEMBL7418341 | 0.80 | HTT (0.37) | KMT2AHTTMAPKAPK2ATR | |
| SCHEMBL10399429 | 0.80 | GABRP (0.40) | KMT2AMAPKAPK2HEXAHEXBDHFR | |
| SCHEMBL28196797 | 0.78 | MAPKAPK2 (0.49) | KMT2AMAPKAPK2HEXAHEXBDHFR | |
| SCHEMBL10394906 | 0.78 | MAPKAPK2 (0.44) | MAPKAPK2HEXAHEXBDHFR | |
| SCHEMBL1585295 | 0.78 | ATR (0.37) | KMT2AHTTMAPKAPK2ATRADORA2A | |
| SCHEMBL1585158 | 0.78 | ACVR1 (0.33) | KMT2AHTTEDNRAATR | |
| SCHEMBL11223672 | 0.77 | CCR4 (0.38) | CCR4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4441042-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118748995-A | 5-Pyrimidine carboxamide derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-08 | — | — | CN | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160967-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| CN-106459067-A | Imidazo[1,2-A]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy | 豪夫迈·罗氏有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| US-6083951-A | FOR THE TREATMENT OF DISEASES OR MEDICAL CONDITIONS SUCH AS HYPERTENSION, PULMONARY HYPERTENSION, CARDIAC OR CEREBRAL CIRCULATORY DISEASE AND RENAL DISEASE | ZENECA LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| EP-0752986-B1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LTD (GB) | 1999-05-19 | — | — | EP | disclosed |
| US-5861401-A | TREATMENT OF CONGESTIVE HEART FAILURE | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| EP-0752986-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026957-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | CCR4 4163/4885KMT2A 2669/4885HTT 3559/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCR4 3928/4885KMT2A 1853/4885HTT 397/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | CCR4 4802/4885KMT2A 2941/4885HTT 1060/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCR4 3928/4885KMT2A 1853/4885HTT 397/4885 |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | CCR4 1289/4885KMT2A 2091/4885HTT 1074/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | CCR4 3979/4885KMT2A 1758/4885HTT 278/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CCR4 3798/4885KMT2A 1654/4885HTT 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.